Real-world experience of efanesoctocog alfa in Hemophilia A patients in the US: A retrospective analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1286
Abstract: Introduction Efanesoctocog alfa is a first-in-class, high-sustained factor VIII (FVIII) replacement therapy designed to overcome the half-life limitations imposed by von Willebrand factor (VWF). In pivotal Phase 3 trials, XTEND-1 (NCT04161495) and XTEND-Kids (NCT04759131), once-weekly… read more here.
Keywords: real world; efanesoctocog; efanesoctocog alfa; chart review ... See more keywords